Updates from EMA, FDA, and UK NICE at the 6-8 Sep 2017 ASM-ESCMID Antibiotic Development Conference

Dear All:

On Wednesday 6 Sep at the ASM-ESCMID Conference on Antibacterial Development, we heard 3 superb back-to-back talks on the evolving regulatory and health technology assessment (HTA) landscape.

The speakers (Marco Cavaleri, PhD, Head of Anti-Infectives and Vaccines, EMA; Sumati Nambiar, MD, Director, Division of Anti-infective Products, FDA; and Colm Leonard, MD, Consultant Clinical Adviser, National Institute for Health and Care Excellence) have kindly agreed to make their presentations available and you can download them here as a 1.5MB .zip file. You’ll want to review the talks yourself, but let me point out these highlights:

  • First and foremost, it is only in the setting of products with a clearly articulated ability to address Unmet Need that (a) the increased risk associated with a smaller program can be justified and (b) a value argument can be articulated on the basis of a small program. This is a critical theme that came through over and over.
  • There is a steady movement by EMA, FDA, and PMDA towards tripartite (Japan, US, EU) harmonization. Not everything can be harmonized, but where possible it is being done. As an example, the CFU/ml cut-off for measuring response in cUTI has been harmonized. This may sound like a small thing, but it has real practical implications for those running clinical trials.
  • EMA will update their antibacterial guidance during 2018. This update will capture things like the newly harmonized cUTI measure just mentioned. I’d also predict updates that move in directions foreshadowed both in the July 2016 EMA PK-PD guidance as well as FDA’s Aug 2017 Unmet Need Guidance. It is great to see the steady evolution in thinking!
  • Approaches to approvals for use in pediatrics likewise continue to evolve. Increasingly, there is recognition that generating age-based PK data is often (not always, but often) all that is needed for antibiotics.
  • FDA will begin to move all breakpoint data from the product label to a website that can be updated as needed much more easily.
  • UK NICE has over the past year become deeply and thoughtfully engaged in evaluating pragmatic approaches to antibiotic HTA that will work with the updated regulatory strategies. The core message here is that antibiotic HTA needs to go beyond focusing solely on the immediate costs of care to consider costs of resistance, societal benefit, and also to model future resistance and usage. These messages parallel those released at the final DRIVE-AB conference.

MANY thanks to our colleagues at these agencies both for being so available to the community and for their steady, multi-year efforts to find a pragmatic path forward that balances Unmet Need with risk. We are truly having conversations now that were not possible even 5 years ago!

Best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

Updating WHO’s Bacterial Priority Pathogen List: Call for advisors

Dear All, Deadline: 15 August 2021: The World Health Organization (WHO) is seeking experts to serve as members of the Advisory Group on the Bacterial Priority Pathogen List (AG BPPL). A “Call for experts” document provides information about the advisory group and the expert profiles being sought for the group. The document also provides information on

FDA-NIAID phage workshop / Social distancing in the 1800s

Dear All, This webinar merits a standalone newsletter! If you are thinking (or working on) phage, then please mark your calendar for an FDA (CBER; Center for Biologics Evaluation and Research) workshop entitled: Science and Regulation of Bacteriophage Therapy: August 30, 2021—September 1, 2021 The purpose of the public workshop is to exchange information with the

Consultants for WHO’s SECURE, Wellcome-ICARS-Danish Gov’t AMR event

Dear All, See below my signature: A 6-month consultancy with WHO to support the the SECURE initiative, a program to assist countries in accessing and sustainably managing new and existing antibiotics needed to cope with antimicrobial resistance (AMR). There’s not much online (yet) about SECURE: the best description I can find is in the Terms of Reference

AMR preparedness: Policy insight & funding call for RNA Readiness and Response (R3)

Dear All, A view from Cambodia: “If we lose this antibiotic, there is no oral treatment left for typhoid here.” Good data drives good policy … it’s a lesson that I’ve really grown to appreciate. With this in mind, Wellcome Trust has just released a report entitled “How drug-resistant infections are undermining modern medicine –

Scroll to Top